Current risk stratification algorithms capture high-risk individuals with classical risk factors or established atherosclerotic cardiovascular disease (ASCVD). However, a clinically relevant proportion of individuals without threshold levels of standard modifiable risk factors (SMuRF) – namely hypertension, dysli...
F. Kahles, B. Kurt, K. Schneider et al.· European Heart Journal· 0 citations
The addition of evolocumab reduced the total number of MACE, providing support for the role of intensive low-density lipoprotein cholesterol lowering to prevent first and subsequent MACE in patients at high cardiovascular risk and no prior MI or stroke.
José C. Nicolau, S. Murphy, Robert P. Giugliano et al.· Journal of the American Coll...· 1 citation
Experimental and translational data suggest that lipoprotein(a) exerts its effects early in the disease course, promoting valve inflammation and calcification before significant stenosis develops, raising the possibility that early lipoprotein(a)-lowering may modify disease progression, a hypothesis now being tested in...
L. Tokgozoglu, M. Kayıkçıoğlu· European Cardiology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.